The Journal of Informed Pharmacotherapy 2001;4:404.
Michelle W. Guy, B.Sc. Pharm, Nilufar Partovi, Pharm.D., FCSHP, Mary H.H. Ensom, Pharm.D., FASHP, FCCP, Michael A. Noble, MD, FRCP(C), Eric M. Yoshida, MD, MHSc, FRCP, FACP(C)
Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada
Canadian Society of Hospital Pharmacists (British Columbia Branch) Residency Research Presentation Night, Vancouver, British Columbia, Canada. May 10, 2000. (Unfunded study).
Post-transplant protocols for HBV prophylaxis using high dose intravenous HBIG (10,000 IU) ± lamivudine are commonly reported. Our centre has previously reported a low dose IM protocol and lamivudine with excellent results. There have been, however, no pharmacokinetic studies of IM HBIG in this setting.
Our objective was to determine the pharmacokinetic profile of IM HBIG in long-term post-transplant recipients to determine a rational dosing protocol.
An outpatient liver transplant clinic at Vancouver General Hospital.
Six patients receiving monthly HBIG IM injections (Nabiâ 1560 IU, n=3; Bay-Hepâ 2170 IU, n=3) for greater than one year were studied. HBIG titers (anti-HBs) were determined three times weekly for four weeks and then twice weekly. The pharmacokinetic parameters were calculated using non-compartment methods.
The outcome measures were pharmacokinetic parameters for IM HBIG injection in stable liver transplant recipients.
The mean half-life of IM HBIG was approximately 10.5 days (range 4-20).
Based on these pharmacokinetic parameters in stable long-term post-transplant patients, a rational dosing protocol can be developed which allows for more appropriate utility of HBIG and improved patient convenience.
Copyright © 2000 by the Journal of Informed Pharmacotherapy. All rights reserved.